Skip to main content
. 2016 Aug 20;7(38):61789–61805. doi: 10.18632/oncotarget.11442

Table 3. FACS analysis of TBG-Dy uptake in orthotopic tumors.

LNCaP Cells/Tumor Treatment Injection % Dy Positive
Cells Untreated N/A 1.5
Tumor 1 TBG-Dy iv 46.0
Tumor 2 TBG-Dy iv 46.3
Tumor 3 TBG-Dy ip 46.7

Mice received 200 nmol/kg TBG-Dy by intraperitoneal (ip) or tail vein (iv) injection 20 h prior to tumor excision and processing.